– Reuters
BMO Capital Upgrades Fate Therapeutics to Outperform, Announces $47 Price Target
BMO Capital analyst Etzer Darout upgrades Fate Therapeutics (NASDAQ:FATE) from Market Perform to Outperform and announces $47 price target.
Related Posts
The NFT Gaming Company Hires Specialized Team To Develop AI Games
The NFT Gaming Company, Inc. ("NFTG" or the "Company"), a company developing a digital gaming platform and community that will offer users the ability to create unique avatars playable in all of the
Why Bed Bath & Beyond Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday’s Mid-Day Session
Gainers
SCYNEXIS, Inc. (NASDAQ: SCYX) shares climbed 68% to $2.8184 after the company announced an exclusive license agreement with GSK for Brexafemme, in which the company will receive an upfront payment of $90 million.
Jack In The Box Q2: 23% Revenue Jump, Positive Net Unit Growth & More
Jack In The Box Inc (NASDAQ:JACK) reported second-quarter FY23 sales growth of 22.8% year-on-year to $395.7 million, beating the consensus of…